Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: 2023

Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer

A. Lalane et al.AACR 2023Download the poster herePoster Presentation

Published 18 April 2023
Categorized as 2023, Myvac, Publication, TG4050

New Data Showing that Transgene and NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023

New Data Showing that Transgene and NEC’s TG4050 induces strong and specific immune responses against tumors presented at AACR 15

Published 18 April 2023
Categorized as 2023, categorie-orpheline, dates, dates, Myvac, Press release, TG4050

A randomized phase II trial of TG4001 plus avelumab versus avelumab alone in recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16 positive anogenital cancers

C. Le Tourneau, et al. AACR 2023 – Download the Poster

Published 17 April 2023
Categorized as -others, 2023, Publication, TG4001, TG4001

Oncolytic virus TG6002 safety and activity after intrahepatic artery administration in patients with liver-dominant metastatic colorectal cancer

A. Samson, et al. AACR 2023 – Download the Poster

Published 17 April 2023
Categorized as -others, 2023, 2025, Publication

Selection of an optimal anti-PD-L1 single domain antibody format for the vectorization into oncolytic vaccinia virus and the generation of bispecific immunomodulators

JB. Marchand et al.AACR 2023Download the poster herePoster Presentation

Published 17 April 2023
Categorized as -others, 2023, Invir.IO, Publication

Transgene – Preclinical Results Showing TG6050, a Novel Oncolytic Virus, induces Tumor Regression by Activating Innate and Adaptive immune responses presented at AACR

Preclinical results showing TG6050 induces tumor regression by activating innate and adaptive immune responses 15

Published 17 April 2023
Categorized as 2023, categorie-orpheline, dates, dates, Press release, TG6050-en

Extracellular vesicles (EV): mediators of therapeutic vaccination? In vivo and in vitro characterization of EVs generated after infection of human and murine cells with therapeutic poxviruses

L. Walther et al.AACR 2023Download the poster herePoster Presentation

Published 16 April 2023
Categorized as -others, 2023, Publication

TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses

JB. Marchand et al.AACR 2023Download the poster herePoster Presentation

Published 16 April 2023
Categorized as 2023, Invir.IO, Publication, TG6050-en

Transgene’s Board of Directors Proposes the Appointment of Carol Stuckley, MBA, as New Independent Director

Appointment of Carol Stuckley as New Independent Director 15

Published 12 April 2023
Categorized as 2023, dates, dates, Press release

Availability of Preparatory Documents for the Combined General Meeting of May 5, 2023

Availability of Preparatory documents for the combined general meeting of May 5, 2023 15

Published 11 April 2023
Categorized as 2023, dates, dates, Press release

Posts pagination

Newer posts Page 1 … Page 3 Page 4 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu